HealthQuill HIV capsid inhibitor
China’s WuXi Biologics, a clinical research organization, has granted global rights to US-based Candid Therapeutics to use the company’s synthetic antibody to fight cancer for an upfront payment of $925 million.
Pharma

Gilead’s once-yearly lenacapavir shot for HIV prevention shows strong promise

HQ Team March 12, 2025: In a significant development for HIV prevention, Gilead Sciences has unveiled promising data from its Phase 1 study.

Read More